Search clinical trials for: CP-4055

Total 795 results

Clavis Pharma

Completed

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Neoplasm Metastasis | Malignant Melanoma

United States, Norway, Sweden
Clavis Pharma

Completed

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Advanced Colorectal Cancer

United Kingdom
Clavis Pharma
Syneos Health; Theradex; CardiaBase; Learn & Confirm

Completed

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Relapsed/Refractory AML

United Kingdom, Spain
Sarepta Therapeutics, Inc.

Terminated

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Belgium, Canada, Spain, United Kingdom, Czechia, Germany, Israel, Bulgaria, France, Italy, Poland, Sweden
Kevin Flanigan
Sarepta Therapeutics, Inc.

Completed

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)

Duchenne Muscular Dystrophy

United States, Korea, Republic of, Italy, United Kingdom, Canada, Poland, Spain, France, Germany, Belgium, Australia, Czechia, Serbia, Greece, Argentina, Bulgaria, Denmark, Hungary, India, Ireland, Israel, Mexico, Russian Federation, ...
Clavis Pharma

Completed

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Malignant Melanoma

United States, Sweden, Norway
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

AML | Hematologic Malignancies

United States, United Kingdom, France, Germany, Italy, Norway
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

Belgium, Italy
Liminal BioSciences Ltd.

Terminated

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Alström Syndrome

United Kingdom
Liminal BioSciences Ltd.

Completed

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

Diabetes | Inflammation and Fibrosis

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Completed

Food Effect Study of DDO-3055 Tablets in Healthy Subjects

Anemia in Chronic Kidney Disease

China
Liminal BioSciences Ltd.

Terminated

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Type 2 Diabetes Mellitus | Metabolic Syndrome

Canada
Sarepta Therapeutics, Inc.

Completed

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

Encephalitis

United States
Sarepta Therapeutics, Inc.

Terminated

Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

Hepatitis C
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease

Chronic Kidney Disease

China
Ono Pharmaceutical Co. Ltd

Completed

A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053

Healthy Adult Male Subjects

United Kingdom
Ono Pharmaceutical Co. Ltd

Completed

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Healthy Adult Subjects

United Kingdom
Ono Pharmaceutical Co. Ltd

Terminated

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Healthy Adult Subjects

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.

Renal Anemia
AO GENERIUM

Recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
Liminal BioSciences Ltd.

Completed

A Healthy Volunteer Study of PBI-4050

Fibrosis | Inflammation

United Kingdom
Gilead Sciences

Completed

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

France, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.

Anemia Associated Chronic Kidney Disease

China
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
Hero Institute for Infant Nutrition
Universidad de Murcia; University of Valencia; Universidad de Granada

Completed

Effects of Probiotics in Immune System of Healthy Adults (SETOPROB)

Conditions Influencing Health Status

Spain
Brigham and Women's Hospital

Recruiting

CP101 for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Terminated

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Obesity

United States, Australia, Canada, Brazil, Slovakia, Czech Republic, Argentina, Germany, Mexico, United Kingdom, Sweden
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Psoriasis

Japan
AO GENERIUM

Completed

A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Siemens Molecular Imaging

Terminated

Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

Breast Cancer

United States
Sarepta Therapeutics, Inc.

Completed

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

Duchenne Muscular Dystrophy

United States
Pfizer

Terminated

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Obesity

Australia, United States, Korea, Republic of, Spain, France, United Kingdom, Germany, Sweden, Argentina, Chile, Mexico
Pfizer

Terminated

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

Obesity

United States, Canada
University of California, San Francisco
California Breast Cancer Research Program

Completed

Telephone-Based Decision Support for Rural Patients

Breast Cancer

United States
Idera Pharmaceuticals, Inc.

Completed

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Renal Cell Carcinoma

United States
Institute for Clinical and Experimental Medicine

Recruiting

Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP (UNLOAD-AMI)

Myocardial Infarction | Shock, Cardiogenic | Remodeling, Ventricular

Czechia
Pfizer

Completed

ACTiF- Assessment of Closed Tibial Fractures

Tibial Fractures

United States, Australia, Canada, Spain, Turkey, Croatia, India, Bosnia and Herzegovina, Japan, Russian Federation, South Africa
GlaxoSmithKline

Completed

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

Malaria

Burkina Faso, Kenya, Tanzania
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Advanced Solid Tumors

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Solid Tumors

United States
Pfizer

Completed

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Sarcoma, Ewing's

United States, United Kingdom
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Pfizer

Terminated

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Obesity

United States
Pfizer

Completed

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Dyslipidemia

United States
Gilead Sciences

Withdrawn

Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Centocor, Inc.

Completed

A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Taiwan, Korea, Republic of

3

Subscribe